
27.84 Delayed Data As of 4:00pm ET | ![]() Today’s Change | 9.24 Today|||52-Week Range 31.60 | +40.78% Year-to-Date |
Myriad Genetics (MYGN) Collaborates to Advance Oncology Care 10:03am / Zacks.com - Paid Partner Content | Myriad Genetics Inc (MYGN) Q2 2021 Earnings Call Transcript Feb 23 / MotleyFool.com - Paid Partner Content |
Myriad Genetics (MYGN) Beats on Q2 Revenues, Earnings in Line Feb 24 / Zacks.com - Paid Partner Content | Myriad Genetics (MYGN) Reports Q2 Loss, Tops Revenue Estimates Feb 23 / Zacks.com - Paid Partner Content |
Previous close | 28.44 |
Today’s open | 28.24 |
Day’s range | 26.79 - 28.45 |
Volume | 42,900 |
Average volume (3 months) | 803,157 |
Market cap | $2.3B |
Earnings growth (last year) | -4,389.30% |
Earnings growth (this year) | -- |
Earnings growth (next 5 years) | +6.00% |
Revenue growth (last year) | -24.97% |
P/E ratio | NM |
Price/Sales | 1.32 |
Price/Book | 2.48 |
Today’s change | Today’s % change | |
---|---|---|
LNTHLantheus Holdings In... | +0.60 | +3.25% |
VCYTVeracyte Inc | +0.73 | +1.56% |
TRILTrillium Therapeutic... | -0.19 | -1.86% |
CLDXCelldex Therapeutics... | +1.07 | +4.25% |
Next reporting date | November 9, 2021 |
EPS forecast (this quarter) | -$0.16 |
Annual revenue (last year) | $638.6M |
Annual profit (last year) | -$199.5M |
Net profit margin | -31.24% |
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Salt Lake City, Utah |